Skip to content

Mindfulness Yoga and Sexual Functioning

The Effect of Mindfulness Yoga on Sexual Functioning for Breast Cancer Survivors

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05461534
Enrollment
78
Registered
2022-07-18
Start date
2022-08-01
Completion date
2024-08-01
Last updated
2022-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Sexual Dysfunction

Brief summary

Female breast cancer survivors with sexual dysfunction were randomly divided into a mindfulness yoga intervention group and a control group, and the investigators aimed to evaluate the effects of mindfulness yoga on sexual function in breast cancer survivors.

Interventions

Each mindfulness yoga session will last for 90 minutes and will be conducted in a group format once a week. Each session includes breathing exercise (10 min), mindfulness meditation and body scan (20 min) and yoga practice (60 min).

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

age 18-65 years; diagnosed with primary breast cancer (stages:T1-T4, N0-N1, M0); individuals who have completed surgery, chemotherapy and radiotherapy (with the exception of immunotherapy and endocrine therapy); without cognitive impairment; diagnosed with sexual dysfunction.

Exclusion criteria

without sexual experience; in pregnancy or lactation; individuals with serious cognitive or psychiatric issues (i.e., depression, alcohol dependency, or psychotic disorders); individuals who are illiterate, with hearing disorder or communication difficulties; individuals with other type of tumors or other serious acute or chronic diseases at the time of enrollment; individuals participate in a concurrent medical treatment or nonmedical treatment targeting sexual problems; individuals participate in a concurrent psychotherapy; individuals with experience in mindfulness or yoga.

Design outcomes

Primary

MeasureTime frameDescription
Change from sexual activity4 weeks (T1), 8 weeks (T2);three months (T3) and six months (T4) after completion of the 8 weeks interventionThe score change of the Sexual Activity Questionnaire(SAQ).The SAQ consists of 10 items and three subscales. Higher pleasure or discomfort subscale score indicated higher levels of pleasure or discomfort, and habit is a single item (0 'less sexual activity than usual' to 3 'much more sexual activity than usual').
Change from Female sexual function index4 weeks (T1), 8 weeks (T2);three months (T3) and six months (T4) after completion of the 8 weeks interventionThe score change of Female Sexual Function Index (FSFI). FSFI consists of 19 items comprising six domains of sexual function (desire, arousal, lubrication, orgasm, satisfaction, and pain). The total score ranges from 0 to 36. Higher score corresponds to better sexual functioning.
Change from Sexual distress4 weeks (T1), 8 weeks (T2);three months (T3) and six months (T4) after completion of the 8 weeks interventionThe change of The Female Sexual Distress Scale-Revised (FSDS-R).The total score ranges from 0 to 48, and a higher score indicates a higher level of sexual distress.

Secondary

MeasureTime frameDescription
Change from Fatigue4 weeks (T1), 8 weeks (T2);three months (T3) and six months (T4) after completion of the 8 weeks interventionThe Brief Fatigue Inventory (BFI) will be used. The total score ranges from 0 to 90. Higher scores on the BFI indicates greater self-reported levels of fatigue.
Change from Body Image4 weeks (T1), 8 weeks (T2);three months (T3) and six months (T4) after completion of the 8 weeks interventionBody Image Subscale (BIS) of the European Organization for Research and Treatment of Cancer Quality of Life-Breast Cancer Module (EORTC- QLQ-BR23) will be used. The total score ranges from 4 to 16, and higher score indicates higher level of body image.
Change from Quality of life (QOL)4 weeks (T1), 8 weeks (T2);three months (T3) and six months (T4) after completion of the 8 weeks interventionThe European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30 (EORTC QLQ-C30) simplified Chinese V3.0 version will be used. The total score ranges from 0 to 100. Higher scores of symptom and financial scales indicates more severe symptoms.
Change from Sleep quality4 weeks (T1), 8 weeks (T2);three months (T3) and six months (T4) after completion of the 8 weeks interventionThe Pittsburgh Sleep Quality Index (PSQI) will be used. The total score ranges from 0 to 21. Higher scores indicate poorer sleep quality.
Change from Anxiety and Depression4 weeks (T1), 8 weeks (T2);three months (T3) and six months (T4) after completion of the 8 weeks interventionThe Hospital Anxiety and Depression Scale (HADS) will be used.Higher HADS-D ( ranges from 0-21) or HADS-A ( ranges from 0-21) score correspond to more serious psychological distress
Change from Menopausal symptoms4 weeks (T1), 8 weeks (T2);three months (T3) and six months (T4) after completion of the 8 weeks interventionThe Endocrine symptom subscale (ESS) of the Endocrine Subscale for The Functional Assessment of Cancer Therapy-Breast (FACT-B ES) will be used. The total score ranges from 0 to 72. Higher score indicates fewer menopausal symptoms

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026